RxDoctor Payments Data

Augustine Izah, MD

Family Medicine · Merrillville, INNPI 1760476303

Payments from drug & device makers

$680in general payments, 2019–2025

Across 8 payments — averaging $85.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$305
  • Phathom Pharmaceuticals, Inc.$93
  • Bayer$89
  • Sanofi$70
  • Novo Nordisk$62
  • Pfizer$61

What the payments were for

  • Speaking & faculty fees$7010%
  • Food & beverage$61090%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$680 in reported general payments places this provider in the 55th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$112,207
Medicare patients
242
Services billed
1,527

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide41$51,246
JanuviaSitagliptin Phosphate34$46,940
FarxigaDapagliflozin Propanediol54$46,661
EntrestoSacubitril/Valsartan40$41,941
EliquisApixaban44$39,820
XareltoRivaroxaban23$32,859
JanumetSitagliptin Phos/Metformin Hcl11$16,609
Combivent RespimatIpratropium/Albuterol Sulfate13$14,320
Lantus SolostarInsulin Glargine,hum.Rec.Anlog131$14,233
LinzessLinaclotide12$13,778
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog32$11,661
Tresiba Flextouch U-100Insulin Degludec18$10,468
JardianceEmpagliflozin13$10,161
MyrbetriqMirabegron19$8,514
Humalog Mix 75-25Insulin Lispro Protamin/Lispro37$5,800

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$62$51,24641 claims
AstraZenecaFarxiga, Symbicort$305$50,55168 claims
PfizerEliquis$61$39,82044 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Merrillville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →